A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation

A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation

Background: The epidermal growth factor receptor (EGFR) gene harbors a variety of pathogenic variants in non-small cell lung cancer (NSCLC) with several mutations within exons 18–21 serving as common targets for tyrosine kinase inhibitor (TKI) therapy. Osimertinib is a third generation TKI that was...

Full description

Bibliographic Details
Main Authors:	Daniel J. Craig, Navkirat K. Kahlon, Danae M. Hamouda
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Current Problems in Cancer: Case Reports
Subjects:	EGFR Tyrosine kinase inhibitors Osimertinib Non-small cell lung cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666621922000527

Similar Items

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy
by: K. A. Sarantseva, et al.
Published: (2020-12-01)

Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells
by: Paulina Skupin-Mrugalska, et al.
Published: (2020-09-01)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
by: Michael Cekay, et al.
Published: (2023-08-01)

Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
by: Leydis Luna Torres, et al.
Published: (2021-10-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
by: Igor Makhlin, et al.
Published: (2019-11-01)

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer
by: Matthew G. Field, et al.
Published: (2022-06-01)

ПРИОБРЕТЕННАЯ РЕЗИСТЕНТНОСТЬ К ИНГИБИТОРАМ ТИРОЗИНКИНАЗЫ EGFR: ПУТИ ПРЕОДОЛЕНИЯ
Published: (2017-11-01)

Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report
by: Sho Mitsuya, MD, et al.
Published: (2024-02-01)

Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report
by: Aurélie Louvet, et al.
Published: (2023-07-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
by: Tia Cheunkarndee, BA, et al.
Published: (2024-06-01)

Relationship of EGFR-TKI Targeted Therapy and Pyroptosis in Non-small Cell Lung Cancer
by: CHEN Jiachen, et al.
Published: (2023-12-01)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion
by: Ayu Kiritani, et al.
Published: (2024-02-01)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
by: Yufeng Li, et al.
Published: (2023-04-01)

Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer
by: Wentao Tian, et al.
Published: (2024-08-01)

The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors
by: Giuseppe Bronte, et al.
Published: (2024-01-01)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
by: Soei Gen, et al.
Published: (2022-06-01)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation
by: Shigetoshi Nishihara, et al.
Published: (2022-07-01)

Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer
by: Beilei Zeng, et al.
Published: (2024-09-01)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
by: Makoto Hibino, MD, et al.
Published: (2022-12-01)

Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
by: Caiyan Jia, et al.
Published: (2024-01-01)

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer
by: Hye Sook Kim, et al.
Published: (2023-06-01)

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review
by: Xiaofei Gu, et al.
Published: (2024-06-01)

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
by: Minehiko Inomata, et al.
Published: (2022-03-01)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023-06-01)

EGFR Mutation as a Predictive Factor to Treatment Response of TKI (Tyrosine Kinase Inhibitor) in Non-Small Cell Lung Cancer Stage 4: A Case Report
by: Wulyo Rajabto, et al.
Published: (2021-03-01)

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
by: Leou Ismael Banla, MD, PhD, et al.
Published: (2023-10-01)

Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study
by: Duanyang Peng, et al.
Published: (2022-12-01)

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report
by: Petros Christopoulos, et al.
Published: (2024-05-01)

Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression
by: Walid Shalata, et al.
Published: (2024-08-01)

The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis
by: Liuxian Guo, et al.
Published: (2024-04-01)

EGFR targeted therapy in lung cancer; an evolving story
by: C. Bartholomew, et al.
Published: (2017-01-01)

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with <i>EGFR</i> Gene Mutation–Case Report and a Literature Review
by: Anna Rekowska, et al.
Published: (2022-05-01)

Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer
by: Takehiro Tozuka, MD, et al.
Published: (2024-04-01)

EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review
by: Chang-Hung Chen, et al.
Published: (2022-11-01)

Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
by: Chunhong Hu, et al.
Published: (2023-01-01)

Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer
by: XU Wenwen, et al.
Published: (2021-12-01)

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells
by: Xiao-Yu Zhang, et al.
Published: (2016-09-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)